September 8, 2011 – Concentric Medical announced completion of enrollment of the TREVO Study. The TREVO Study (Thrombectomy REvascularization of large Vessel Occlusions in acute ischemic stroke) is the first evaluation of Stentriever technology in a European, multicenter, prospective clinical trial. The TREVO Study was designed to assess the ability of the Trevo System to remove the blood clots that cause strokes and to restore blood flow to the brain.
The TREVO Study employed the latest generation of the Trevo Retrieval System and the preliminary results are very promising. Interim data from the study were presented in May at the European Stroke Congress by professor Olav Jansen, head of neuroradiology at Universitatsklinikum Schleswig-Holstein Kiel. The interim revascularization rate in the first 36 patients was 96 percent. Thirty patients had 90-day follow up and 63 percent of these had a good outcome. A "good outcome" was defined as being functionally independent at 90 days (modified Rankin score of 2 or less).
Jansen and professor Nils Wahlgren, professor of neurology at Karolinska University Hospital, are co-principal investigators of the study. Wahlgren said, "The TREVO study represents an important step forward in the evidence supporting the treatment of patients with moderate and severe strokes with mechanical thrombectomy devices, such as the Trevo System. The rigorous conduct of this prospective multicenter trial provides more confidence not only in patient selection, but in the successful procedural and clinical outcomes for these patients."
"The Trevo System is the first device of this type designed specifically for removal of the clot in ischemic stroke patients. Not only was it easy to use, but the architectural properties of the device enhance clot integration into the device, making the procedures fast and remarkably effective," said Juan Macho, M.D., Ph.D., of Hospital Clinic Barcelona.
For more information: www.concentric-medical.com
November 18, 2024 
